Page 6 of 6
combination of TQ and DHA-PQP was better than DHA-PQP alone in treating
Indonesian men with P. vivax malaria. No serious side effects were reported by patients
who received TQ. Non-serious side effects reported during this study were similar to
those expected with TQ.
Are there plans for further studies?
Other studies on TQ in patients with malaria have been conducted and more are
underway.
Where can I find more information about this study?
Clinical studies have unique study numbers that are included in publications and other
information about the study. The unique study number associated with this study is
shown below with an internet link to the scientific summary and other information.
The scientific summary includes more details about the requirements for study
enrolment, the study visit schedule, results from other endpoints, and more detailed
information about adverse events.
Organisation and Website Study Number
United States National Institutes of Health (NIH)
NCT028025011
(www.clinicaltrials.gov)
Your doctor can help you understand more about this study and the results. Speak to
your doctor about the treatment options available in your country. You should not
make changes to your care based on the results of this or any single study. Keep taking
your current treatment unless instructed by your doctor.
We would like to thank the patients who contributed to this study. The results of this
study will help answer scientific questions about treating patients with P. vivax malaria.
The content for this document was finalised by GSK on 23rd of July 2020. The
information in this summary does not include additional information available after this
date.
1https://clinicaltrials.gov/ct2/show/study/NCT02802501